Ann: Acrux announces commercial agreement with Padagis, page-15

I must be slipping!! Have just noticed that Dash Pharma was bought out and is now a holly owned subsidiary of Natco Pharma, effective 1st Jan 2022. Sale price was US$18 million. That's good in one way as Natco is listed on the NY Stock Exchange. So I've had a look at Natco's Jan to March 2022 QTR Financials, but unfortunatly there is no breakdown of revenue streams from subsidiary's nor a break down individual drug products. So I have sent a request to Natco as to where I can obtain this information. Being a public company it should be readily available. I'll keep you all posted. So with all that happens during a takeover I can only hope that the Dash Pharma Team were not distracted too much when it comes to our testosterone interests.